X年全国性病实验室工作总结及X年性病实验室工作

Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,*,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,*,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,*,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,*,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,*,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,*,2012,年全国性病实验室工作总结,2013,年,全国,性病实验室工作,要求,尹跃平,中国疾病预防控制中心性病控制中心,中国医学科学院皮肤病研究所,全国性病参比实验室,2012,年,4,月,01,日 山东济南,2012,年全国性病实验室工作,2,2012,年全国性病防治工作要点,实验室部分,1.,省级性病中心实验室建设。,2.,参加,国家,性病实验室检测的能力验证,3.,省级性病中心实验室组织辖区内梅毒检测能力验证考核。,4.,淋球菌耐药监测点按照要求完成淋球菌耐药检测任务,5.,试剂评估,。,3,2012年全国艾滋病性病防治主要措施落实质量,考核,指标,17,：,性病实验室能力验证参与率及合格率,2012,年性病防治综合奖评奖依据之一,1,、,省级性病中心实验室建设,4,通过现场和考核验收省份,海南省皮肤性病防治中心,云南省疾病预防控制中心,江苏省疾病预防控制中心,广东省性病防治控制中心,天津省疾病预防控制中心,省级性病中心实验室基本要求,1,、实验室质量管理（,60%,）,：,组织开展本行政区域性病实验室质量管理,吗。包括实验室质控、培训、督导等方面的工作。,2,、硬件要求（,40%,）,：人员、空间、设备以及其基本的实验室操作技术，相应的制度、程序。,疾控机构：加强自身能力建设,皮防机构：加强全省指导管理能力,省份,梅毒,淋球菌,衣原体,总分,北京市,25.0,12.5,12.5,50.0,天津市,25.0,12.5,12.5,50.0,河北省,25.0,12.5,12.5,50.0,辽宁省,25.0,12.5,12.5,50.0,吉林省,25.0,12.5,12.5,50.0,黑龙江省,25.0,12.5,12.5,50.0,上海市,25.0,12.5,12.5,50.0,江苏省,25.0,12.5,12.5,50.0,浙江省,25.0,12.5,12.5,50.0,福建省,25.0,12.5,12.5,50.0,山东省,25.0,12.5,12.5,50.0,海南省,25.0,12.5,12.5,50.0,宁夏回族自治区,25.0,12.5,12.5,50.0,2.,参加,国家,性病实验室检测的能力验证,结果,2.,参加,国家,性病实验室检测的能力验证,结果,参加实验室的要求：,省级性病中心实验室负责组织,本省一家省级综合医疗机构,(,如省人民医院,),国家淋球菌耐药监测点,各性病监测点两家医疗机构,3.,各省组织省内,梅毒,质控情况,省份,单位数,参加率,%,合格率,%,得分,省份,单位数,参加率,%,合格率,%,得分,天津市,81,100.0,100.0,50.0,山东省,405,88.5,94.2,45.7,江苏省,525,100.0,100.0,50.0,上海市,183,84.2,98.1,45.6,浙江省,425,100.0,99.5,49.9,宁夏,80,100.0,81.3,45.3,广东省,376,97.9,100.0,49.5,河南省,314,79.6,99.6,44.8,新疆,252,100.0,97.6,49.4,海南省,71,87.3,85.5,43.2,湖南省,216,100.0,96.8,49.2,山西省,367,73.0,97.8,42.7,广西,367,100.0,96.7,49.2,福建省,270,67.0,100.0,41.8,重庆市,181,96.0,100.0,49.0,安徽省,348,71.6,90.8,40.6,北京市,149,100.0,95.3,48.8,陕西省,210,61.0,96.9,39.5,河北省,561,94.8,100.0,48.7,辽宁省,461,16.3,100.0,29.3,吉林省,170,92.5,99.2,47.9,青海省,192,3.1,100.0,25.8,云南省,460,94.8,96.6,47.9,四川省,387,43.2,96.4,34.9,甘肃省,358,89.1,99.7,47.2,黑龙江省,0.0,内蒙古,372,92.5,93.0,46.4,贵州省,0.0,江西省,382,84.0,100.0,46.0,西藏,0.0,湖北省,411,84.7,99.1,46.0,8,2012年全国艾滋病性病防治,考核,指标,17,省份,参与性病控制中心质控得分,省内组织梅毒质控得分,总分,省份,参与性病控制中心质控得分,省内组织梅毒质控得分,总分,天津,50.0,50.0,100.0,新疆,44.6,49.4,94.0,江苏,50.0,50.0,100.0,江西,47.9,46.0,93.9,浙江,50.0,49.9,99.9,海南,50.0,43.2,93.2,北京,50.0,48.8,98.8,云南,44.0,47.9,91.8,河北,50.0,48.7,98.7,福建,50.0,41.8,91.8,吉林,50.0,47.9,97.9,河南,45.4,44.8,90.2,广西,47.5,49.2,96.7,安徽,49.0,40.6,89.6,山东,50.0,45.7,95.7,山西,40.6,42.7,83.3,上海,50.0,45.6,95.6,辽宁,50.0,29.1,79.1,湖北,49.5,46.0,95.4,陕西,38.0,39.5,77.5,宁夏,50.0,45.3,95.3,青海,47.9,25.8,73.7,重庆,45.9,49.0,94.9,黑龙江,50.0,0.0,50.0,湖南,45.6,49.2,94.8,四川,0.0,34.9,34.9,广东,45.2,49.5,94.7,贵州,32.8,0.0,32.8,内蒙,47.7,46.4,94.1,西藏自治,25.0,0.0,25.0,甘肃,46.9,47.2,94.1,全国平均,85.4,4,、,2012,年我国,各点,对,5,种抗生素的敏感性,耐 药,监测点,检 测,菌株数,（株）,大观霉素,环丙沙星,头孢曲松,青霉素,四环素,耐药,株数（,%,）,敏感,株数,（,%,）,耐药,株数,(%),中敏,株数,(%),敏感,株数,(%),耐药,株数,(%),中敏,株数,(%),敏感,株数,(%),阳性,株数,(%),阳性,株数,(%),上海,99,0(0.0),99(100.0),98(99.0),1(1.0),0(0.0),0(0.0),21(21.2),78(78.8),47(47.5),47(47.5),深圳,168,0(0.0),168(100.0),160(95.2),3(1.8),5(3.0),0(0.0),33(19.6),135(80.4),50(29.8),73(43.5),新疆,43,0(0.0),43(100.0),43(100.0),0(0.0),0(0.0),0(0.0),10(23.3),33(76.7),15(34.9),10(23.3),广州,100,0(0.0),100(100.0),97(97.0),3(3.0),0(0.0),0(0.0),24(24.0),76(76.0),33(33.0),46(46.0),浙江,100,0(0.0),100(100.0),100(100.0),0(0.0),0(0.0),0(0.0),39(39.0),61(61.0),51(51.0),45(45.0),广东,121,0(0.0),121(100.0),119(98.3),2(1.7),0(0.0),0(0.0),16(13.2),105(86.8),53(43.8),58(47.9),海南,113,0(0.0),113,（,100.0),98(86.7),15(13.3),0(0.0),0(0.0),79(69.9),34(30.1),37(32.7),47(41.6),天津,105,0(0.0),105(100.0),105(100.0),0(0.0),0(0.0),2(1.9),32(30.5),71(67.6),24(22.9),17(16.2),四川,102,0(0.0),102(100.0),100(98.0),2(2.0),0(0.0),0(0.0),21(20.6),81(79.4),70(68.6),57(55.9),大连,110,0(0.0),110(100.0),110(100.0),0(0.0),0(0.0),0(0.0),43(39.1),67(60.9),36(32.7),30(27.3),广西,56,0(0.0),56(100.0),54(96.4),2(3.6),0(0.0),0(0.0),9(16.1),47(83.9),20(35.7),28(50.0),南京,119,0(0.0),119,（,100.0,）,119,（,100.0,）,0(0.0),0(0.0),0(0.0),58,（,48.7,）,61,（,51.3,）,44,（,37.0,）,50,（,42.0,）,合计（,%,）,1236,0(0.0),1236(100.0),1203(97.3),28(2.3),5(0.4),2(0.2),385(31.1),849(68.7),480(38.8),508(41.1),9,耐 药,监测点,2012,年完成,检测菌株数,上海,99,深圳,168,新疆,43,广州,100,浙江,100,广东,121,海南,113,天津,105,四川,102,大连,110,广西,56,南京,119,总计,1236,4,、全国淋球菌耐药监测,12,个监测点参与耐药检测系统,1236,分离株进行耐药（,MIC,）检测,两种推荐药物（壮观霉素、头孢曲松）耐药发生率相对较低（,2012,年发现,2,株头孢曲松耐药菌株,）,但头孢曲松低敏率逐年上升，处于较高水平,5,、,2012,年梅毒血清学检测试剂评估,16,个厂家的,22,种检测试剂进行评估,梅毒螺旋体抗原血清学试验：,ELISA=9,种；快速检测,=7,种；化学发光,=1,种,梅毒螺旋体抗原血清学试验：,TRUST=5,种,参与单位：,广西壮族自治区皮肤病防治研究所,辽宁省疾病预防控制中心,江西省疾病预防控制中心,山东省皮肤病性病防治研究所,江西省皮肤病专科医院,工作、学习交流的一个平台,11,2012,年全国梅毒诊断试剂临床质量评估情况介绍,(,评估结果：非梅毒螺旋体抗